Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics N.V (PRQR) EPS (Basic): 2021-2025

Historic EPS (Basic) for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to $0.12.

  • ProQR Therapeutics N.V's EPS (Basic) rose 6.45% to $0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.71, marking a year-over-year decrease of 1.97%. This contributed to the annual value of -$0.34 for FY2024, which is 9.68% up from last year.
  • Latest data reveals that ProQR Therapeutics N.V reported EPS (Basic) of $0.12 as of Q3 2025, which was up 186.06% from -$0.14 recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics N.V's EPS (Basic) ranged from a high of $0.33 in Q3 2022 and a low of -$1.65 during Q4 2022.
  • Its 3-year average for EPS (Basic) is -$0.10, with a median of -$0.03 in 2024.
  • In the last 5 years, ProQR Therapeutics N.V's EPS (Basic) plummeted by 655.69% in 2022 and then spiked by 58.99% in 2023.
  • Quarterly analysis of 5 years shows ProQR Therapeutics N.V's EPS (Basic) stood at $0.30 in 2021, then tumbled by 655.69% to -$1.65 in 2022, then skyrocketed by 58.99% to -$0.68 in 2023, then increased by 13.29% to -$0.59 in 2024, then rose by 6.45% to $0.12 in 2025.
  • Its last three reported values are $0.12 in Q3 2025, -$0.14 for Q2 2025, and -$0.11 during Q1 2025.